This record was last updated January 23, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a Phase I, single-center, randomized, open-label, parallel-controlled study, aimed at evaluating the pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of a single dose of CM383 administered via intravenous infusion or subcutaneous injection in healthy male subjects.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-15.
Status change: Not Yet Recruiting → Recruiting2026-01-22